Text Size

Comparing Highly Purified hMG With Recombinant FSH + Recombinant LH in Women Undergoing Intrauterine Insemination.

This study has been completed.
Sponsor:
Information provided by:
Instituto Valenciano de Infertilidad, Spain
ClinicalTrials.gov Identifier:
NCT00820482
First received: January 8, 2009
Last updated: September 17, 2009
Last verified: September 2009
History of Changes
  Purpose

The present study aims to elucidate if the FSH and LH activity contained in hMG preparations is comparable to the recombinant FSH and LH administration in a 1:1 ratio. The mean outcome is the corresponding ovarian response in terms of oestradiol increase during stimulation and number of mature follicles the day of hCG administration. The patients will be included and randomized into two groups and stimulated either by HMG injections started on day 3 at a dose of 75 IU every day and fixed for the first 5 days, and in the second group, rFSH and rLH injections be started on day 3 at a dose of 75 UI/day of rFSH + 75UI/day of rLH. Serum estradiol levels will be measured on stimulation day 1, day 6 and the day of hCG injection. All follicles greater than 14 mm of diameter will be recorded on hCG day Intrauterine insemination is performed during two consecutive days starting the day after the human chorionic gonadotrophin (Ovitrelle) injection. Secondary outcomes are Days of stimulation, Total doses of gonadotrophins administrated, Clinical pregnancy , Ongoing pregnancy and Miscarriage rate, and Cancellation rate.


Condition Intervention Phase
Ovarian Stimulation Preceding Intrauterine Insemination
 Drug: Menopur®, Ferring
Drug: rFSH (Gonal®,
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Controlled Trial Comparing Highly Purified hMG With Recombinant FSH + Recombinant LH in Women Undergoing Intrauterine Insemination: Ovarian Response and Clinical Outcomes.

Resource links provided by NLM:

Drug Information available for: Menotropins
U.S. FDA Resources

Further study details as provided by Instituto Valenciano de Infertilidad, Spain:

Primary Outcome Measures:
  • The present study aims to elucidate if the FSH and LH activity contained in hMG preparations is comparable to the recombinant FSH and LH administration in proporción 1:1. Mean outcome: - Ovarian response according to the protocol used. [ Time Frame: one month ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Secondary outcomes: - Days of stimulation - Total doses of gonadotrophins administrated - Clinical pregnancy , ongoing pregnancy and miscarriage rate - Cancellation rate [ Time Frame: one cycle ] [ Designated as safety issue: No ]

Estimated Enrollment: 80
Study Start Date: January 2009
Study Completion Date: May 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Group A
Group A: 75 UI/day of Hp-hMG (Menopur®, Ferring, Copenhaghen, Dinamarca)
 Drug: Menopur®, Ferring
75 UI/day of Hp-hMG (Menopur®)
Experimental: Group B
75UI/day of rFSH (Gonal®, Serono, Ginebra, Suiza) + 75UI/day of rLH (Luveris®, Serono, Ginebra, Suiza)
 Drug: rFSH (Gonal®,
75UI/day of rFSH (Gonal®, Serono) + 75UI/day of rLH (Luveris®, Serono)

  Eligibility

Ages Eligible for Study:   18 Years to 39 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Esterility > 1 year duration
  • < 39 years old
  • REM > 3 millions/ml
  • 1 or 2º IUI cycle

Exclusion criteria:

  • Ovarian policystic syndrome
  • Severe Endometriosis
  • Uterine disease (polyps, myomas, intracavitarios, malformations…)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00820482

Locations
Spain
IVI Valencia
Valencia, Spain, 4
IVI Valencia
Valencia, Spain, 46117
Sponsors and Collaborators
Instituto Valenciano de Infertilidad, Spain
Investigators
Principal Investigator: Elena Labarta, MD IVI Valencia
  More Information

No publications provided

Responsible Party: Dr. Elena Labarta, Instituto Valenciano de Infertilidad, Spain
ClinicalTrials.gov Identifier: NCT00820482     History of Changes
Other Study ID Numbers: VLC- EL-0106-307-9
Study First Received: January 8, 2009
Last Updated: September 17, 2009
Health Authority: Spain: Comité Ético de Investigación Clínica

Additional relevant MeSH terms:
Menotropins
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
 Physiological Effects of Drugs
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on May 23, 2013